Senseonics Holdings, Inc. (SENS)
After hours:
| Previous close | 0.5045 |
| Open | 0.5012 |
| Bid | 0.5000 x 1800 |
| Ask | 0.5100 x 1100 |
| Day's range | 0.5006 - 0.5170 |
| 52-week range | 0.3840 - 1.0500 |
| Volume | |
| Avg. volume | 2,655,545 |
| Market cap | 265.993M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.63 |
ZacksClover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. to Participate in Upcoming Conferences
GERMANTOWN, Md., May 02, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference, being held in New York, NY.
Business WireSenseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial results after market close on Monday, May 13, 2024.
